Symptomtext
administered an ActHIB vaccine that was later noted to have expired on 10/15/2022 with no reported adverse event; Initial information was received on 10-Nov-2022 regarding an unsolicited valid non-serious case from a other health professional. This case involves 15 months old female patient who was administered by an HAEMOPHILUS TYPE B (HIB) VACCINE (prp/t) vaccine [Act-Hib] vaccine that was later noted to have expired on 10/15/2022 with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s), concomitant disease or risk factor and family history were not provided. Concomitant medications included influenza vaccine inact split 4v (Fluzone quadrivalent) for prophylactic vaccination (Immunisation); pneumococcal vaccine conj 7v (crm197) (Prevnar) and diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (Dtap) for unknown indication. On 10-Nov-2022, the patient was administered by 0.5 ml dose 4 of suspect HAEMOPHILUS TYPE B (HIB) (prp/t) vaccine (formulation: unknown, strength: standard, lot number: UJ583ABB, expiry date 15-Oct-2022) via intramuscular route in the right arm for Immunisation that was later noted to have expired (expired product administered) with no reported adverse event (latency: same day). No lab data reported. Action taken: not applicable. It was not reported if the patient received a corrective treatment for the event. Outcome: Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.